UBS keeps Buy rating for Tecan stock at CHF 255.00

Published on 10/01/2026 at 17:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Tecan posted CHF 427.50 million sales in first-half 2026, up 3.40 percent. Tecan stock costs EUR 246.20 on October 1, 2026 after EUR 246.10.

Architektur-Render eines modernen Forschungs- und Entwicklungsgebäudes mit Glasfassade — Tecan Group AG (CH0012100191) im Laborautomationssektor: modernes Architektur-Render eines Forschungsgebäudes mit Glasfassade präsentiert, Illustration mit AI erstellt.

Tecan stock was at EUR 246.20 at Lang & Schwarz on October 1, 2026 at 5:00 p.m. CEST, up 0.04 percent versus the prior close of EUR 246.10. Markets Insider reported on September 28, 2026 that UBS maintained a Buy rating and set a CHF 255.00 price target.

UBS target meets a mixed market

The UBS target stands above the latest SIX reference price of CHF 231.20, which was last quoted at 4:42 p.m. CEST on October 1, 2026. The same primary-exchange quote showed a 52-week range of CHF 110.60 to CHF 237.20, placing the share near the upper end of that span.

Markets Insider also reported on September 24, 2026 that Deutsche Bank raised its Tecan target from CHF 176.00 to CHF 198.00 while keeping a Hold rating. That split between a CHF 198.00 Hold target and UBS at CHF 255.00 makes execution against the operating plan the central valuation question.

First-half margin provides the evidence

According to Tecan in its August 11, 2026 results release, first-half 2026 sales reached CHF 427.50 million, down 2.70 percent in Swiss francs but up 3.40 percent in local currencies. Both the Life Sciences Business and Partnering Business contributed growth, at 3.10 percent and 3.60 percent in local currencies.

Tecan reported an adjusted EBITDA margin of 15.10 percent for the first half of 2026, compared with 15.00 percent in the first half of 2025. The company confirmed full-year 2026 guidance for low-single-digit sales growth in local currencies and an adjusted EBITDA margin of 15.50 to 16.50 percent.

Next results date is November 5

Tecan's investor calendar lists a qualitative update for the third quarter of 2026 on November 5, 2026, giving investors a defined checkpoint for sales momentum and margin delivery. The company operates in laboratory automation and medical instruments, with its products serving life-science research, diagnostics and pharmaceutical customers.

At 5:00 p.m. CEST on October 1, 2026, the Lang & Schwarz quote was EUR 246.20, plus 0.04 percent versus the prior close of EUR 246.10. The further course of trading is shown by the continuously updated real-time quote of Tecan stock.